The emerging role of bisphosphonates in the prevention of bone metastases

Trends in Endocrinology and Metabolism

Volumn 10, Issue 1, 1999, Pages 24-29

  Paterson, Alexander H G ^a  

^a TOM BAKER CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; PAMIDRONIC ACID;

BONE BIOPSY; BONE METASTASIS; BONE PAIN; BONE REMODELING; BONE TURNOVER; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0033055211     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(98)00097-6     Document Type: Review

References (57)

1. Milas L., Tofilon P. Tumour metastasis: biology and experimental therapeutic approaches. Paterson A.H.G., Lees A.W. Fundamental Problems in Breast Cancer. 1987;283-298 Martinus Nijhof Publishing.
2. Orr F.W., Varani J., Gondetz M.D., Ward P.A., Mundy G.R. Chemotactic responses of tumour cells to products of resorbing bone. Science. 203:1979;176-179.
3. Wicha M.S., Liotta L.A., Vonderhaar B.K., Kidwell W.R. Effects of inhibition of basement membrane collagen deposition on rat mammary gland development. Dev. Biol. 80:1980;253-266.
4. Mundy G.R. Bone resorption and turnover in health and disease. Bone. 8( 1):1987;S9.
5. Kanis J.A., McCloskey E.V. Bone turnover and biochemical markers in malignancy. Cancer. 80( 8):1997;1538-1545.
6. Mundy G.R. Hypercalcemia of malignancy revisited. J. Clin. Invest. 82:1988;1-6.
7. Berruti A.et al. Pamidronate administration improves the secondary hyperparathyroidism due to 'bone hunger syndrome' in a patient with osteoblastic metastases from prostate cancer. Prostate. 1:1997;252-255.
8. Kanis J.A., Percival R.C., Yates A.J.P., Urwin G.H., Handy N.A.T. Effects of diphosphonates in hypercalcaemia due to neoplasia. Lancet. i:1986;615-616.
9. Kamenor B., Kieran M.W., Barrington-Leigh J., Longenecker B.M. Homing receptors as functional markers for classification, prognosis, and therapy of leukaemia and lymphomas. Proc. Soc. Exp. Biol. Med. 177:1984;211-219.
10. Paget J. The distribution of secondary growths in cancer of the breast. Lancet. i:1889;571-573.
11. Batson O.V. The function of the vertebral veins and their role in the spread of metastases. Ann. Surg. 112:1940;138.
12. Paterson A.H.G. Natural history of skeletal complications of breast cancer, prostate cancer and myeloma. Bone. 8( 1):1987;S17.
13. Valentin-Opran A., Edouard C., Charhon S., Meunier P. Histomorphometric analysis of iliac bone metastases of prostatic origin. Symposium CEMO III Bone and Tumours Geneva Editions, Medicine and Hygiene. 1980;24-28.
14. Jacobs S.C., Lawson R.K. Mitogenic factor in human prostate extracts. Urology. 16:1980;488.
15. Goltzman D. Mechanisms of the development of osteoblastic metastases. Cancer. 80( 8):1997;1581-1587.
16. Elomaa I., Blomqvist C., Porrka L., Lamberg-Allardt C., Bergstrom G.H. Treatment of skeletal disease in breast cancer: a controlled clinical trial. Bone. 8( 1):1987;S53.
17. van Holten-Verzantvoort A.T.et al. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonates (APD) treatment. Lancet. 11:1987;983-985.
18. Paterson A.H.G., Powles T.J., Kanis J.A., McCloskey E., Hanson J., Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J. Clin. Oncol. 11:1993;59-65.
19. McCloskey E.V.et al. The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos. Int. 3:1993;138-147.
20. Coleman R.E., Woll P.J., Miles M., Scrivener W., Rubens R.D. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD). Br. J. Cancer. 58:1988;621-625.
21. Conte P.F.et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J. Clin. Oncol. 14:1996;2552-2559.
22. Hortobagyi G.N.et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New Engl. J. Med. 335:1996;1785-1791.
23. Delmas P.D. The use of clodronate in multiple myeloma. Bone. 12( 1):1991;S31.
24. Clemens M.R., Fessele K., Heim M.E. Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications. Ann. Hematol. 66:1993;141-146.
25. Berenson J.R.et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New Engl. J. Med. 334:1996;488-493.
26. Adami S., Mian M. Clodronate therapy of metastatic bone disease in patients with prostate cancer. Recent Results Cancer Res. 116:1989;567-572.
27. Vorruether R. Bisphosphonates as an adjunct to palliative therapy of bone metastases from prostate cancer. Br. J. Urol. 72:1993;792-795.
28. Fernandez-Conde M.et al. Skeletal response to clodronate in prostate cancer with bone metastases. Am. J. Clin. Oncol. 20:1997;471-476.
29. Ernst D.S., MacDonald N., Paterson A.H.G., Jenson J., Brasher P., Bruera E. A double-blind cross-over trial of intravenous clodronate in metastatic bone pain. J. Pain Symptom Management. 7:1992;4-11.
30. Ernst D.S., Brasher P., Hagen N., Paterson A.H.G., MacDonald N., Bruera E. A randomized, controlled trial of intravenous clodronate in metastatic bone disease and pain. J. Pain Symptom Management. 13:1997;319-326.
31. van Holten-Verzantvoort A.T.et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur. J. Cancer. 27:1991;544-549.
32. Selander K.S., Monkkonen J., Karhukorpi E.K., Harkonen P., Hannuniemi R., Vaananen H.K. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol. Pharmacol. 50:1996;1127-1138.
33. Shipman C.M., Rogers M.J., Apperley J.F., Russel R.G., Croucher P.I. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br. J. Haematol. 98:1997;665-672.
34. Goldhirsch A.et al. Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet. 343:1994;377-381.
35. Powles T.J., McCloskey E., Paterson A.H.G., Ashley S., Tidy A., Kanis J.A. Oral clodronate will reduce the loss of bone mineral density in women with primary breast cancer. Am. Soc. Clin. Oncol. 16:1997;460 (abstr.).
36. Delmas P.D., Balena R., Confraveux E. Bisphosphonate residronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J. Clin. Oncol. 15:1997;955-962.
37. Wronski T.J., Dann L.M., Qi H., Yen S.F. Skeletal effects of withdrawal of estrogen and diphosphonate treatment in ovariectomised rats. Calcif. Tissue Int. 53:1993;210-216.
38. Fisher B.et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumours. New Engl. J. Med. 320:1989;479-484.
39. Turken S., Siris E., Seldin D., Flaster E., Hyman G., Lindsay R. Effects of tamoxifen on spinal bone density in women with breast cancer. J. Natl. Cancer Inst. 81:1989;1086-1088.
40. Powles T.J., Muindi J., Coombes C. Mechanisms for development of bone metastases and effects of anti-inflammatory drugs. Powles T.J. Prostaglandins and Cancer: First International Conference. 1982;541-543 Alan R. Liss.
41. Mundy G.R. Mechanisms of bone metastasis. Cancer. 80( 8):1997;1546-1556.
42. Siwek B., Lacroix M., DePllak C., Marie P., Body J.J. Secretory products of breast cancer cells specifically affect human osteoblastic cells: partial characterization of active factors. J. Bone Miner. Res. 12:1997;552-560.
43. Pecherstorfer M.et al. Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J. Nucl. Med. 34:1993;1039-1044.
44. Macro M., Bouvard G., LeGangneux E., Colin T., Loyau G. Intravenous aminohydroxy-propylidine bisphosphonate does not modify 99m Tc-hydroxymethylene bisphosphonate bone scintigraphy. A prospective study. Rev. Rheum. Engl. Ed. 62:1995;99-104.
45. Hughes D.E.et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 10:1995;1478-1487.
46. Vitte C., Fleisch H., Guenther H.L. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology. 137:1996;2324-2333.
47. Nishikawa M.et al. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone. 18:1996;9-14.
48. Rogers M.J.et al. Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide independent mechanism. J. Bone Miner. Res. 11:1996;1482-1491.
49. Krempien B. Morphological findings in bone metastatis, tumorosteopathy and anti-osteolytic therapy. Diel I.J., Kaufmann M., Bastert G. Metastatic Bone Disease. Fundamental and Clinical Aspects. 1994;Springer.
50. Yoneda T., Sasaki A., Mundy G. Osteolytic bone metastasis in breast cancer. Breast Cancer Res. Treat. 32:1994;72-84.
51. van der Pluijm G., Vloedgraven H., van Beek E., van der Wee-Pals L., Lowek C., Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J. Clin. Invest. 98:1996;698-705.
52. Boissier S.et al. Bisphosphonates inhibit prostate and breast cancer cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 57:1997;3890-3894.
53. Saarto T., Blomqvist C., Valimaki M., Makela P., Sarna S., Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J. Clin. Oncol. 15:1997;1341-1347.
54. Kanis J.A.et al. Clodronate and skeletal metastases. Bone. 19:1996;663-667.
55. van Holten-Verzantvoort A.T.et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients? Eur. J. Cancer. 32( A):1996;450-454.
56. Diel I.J., Solomeyer E.F., Goerner R., Gollan C., Wallweiner D., Bastea G. Adjuvant treatment of breast cancer patients with the bisphosphonate clodronate reduces incidence and number of bone and non-bone metastases. Proc. Am. Soc. Clin. Oncol. 16:1997;461 (abstr.).
57. Diel I.J.et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J. Natl. Cancer Inst. 88:1996;1652-1658.